Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice.

Yamada ES, Respondek G, Müssner S, de Andrade A, Höllerhage M, Depienne C, Rastetter A, Tarze A, Friguet B, Salama M, Champy P, Oertel WH, Höglinger GU.

Exp Neurol. 2014 Mar;253:113-25. doi: 10.1016/j.expneurol.2013.12.017. Epub 2014 Jan 3.

2.

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Escobar-Khondiker M, Höllerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, Höglinger GU.

J Neurosci. 2007 Jul 18;27(29):7827-37.

3.

Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice.

Rottscholl R, Haegele M, Jainsch B, Xu H, Respondek G, Höllerhage M, Rösler TW, Bony E, Le Ven J, Guérineau V, Schmitz-Afonso I, Champy P, Oertel WH, Yamada ES, Höglinger GU.

J Neurochem. 2016 Nov;139(4):624-639. doi: 10.1111/jnc.13835. Epub 2016 Sep 16.

PMID:
27569447
4.

Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.

Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM.

J Neurosci. 2004 May 12;24(19):4657-67.

5.

Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.

Kulic L, Wollmer MA, Rhein V, Pagani L, Kuehnle K, Cattepoel S, Tracy J, Eckert A, Nitsch RM.

Neurobiol Aging. 2011 Oct;32(10):1827-38. doi: 10.1016/j.neurobiolaging.2009.10.014. Epub 2009 Nov 25.

PMID:
19942317
6.

Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model.

Krishnamurthy PK, Johnson GV.

J Biol Chem. 2004 Feb 27;279(9):7893-900. Epub 2003 Dec 2.

7.

Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation.

Miyasaka T, Morishima-Kawashima M, Ravid R, Heutink P, van Swieten JC, Nagashima K, Ihara Y.

Am J Pathol. 2001 Feb;158(2):373-9.

8.

Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.

Yotsumoto K, Saito T, Asada A, Oikawa T, Kimura T, Uchida C, Ishiguro K, Uchida T, Hasegawa M, Hisanaga S.

J Biol Chem. 2009 Jun 19;284(25):16840-7. doi: 10.1074/jbc.M109.003277. Epub 2009 Apr 28.

9.

Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.

Uno Y, Iwashita H, Tsukamoto T, Uchiyama N, Kawamoto T, Kori M, Nakanishi A.

Brain Res. 2009 Nov 3;1296:148-63. doi: 10.1016/j.brainres.2009.08.034. Epub 2009 Aug 19.

PMID:
19698704
10.

Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.

Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B.

Neurodegener Dis. 2013;11(4):194-205. doi: 10.1159/000338152. Epub 2012 Jul 10.

PMID:
22797329
11.

Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.

Höllerhage M, Matusch A, Champy P, Lombès A, Ruberg M, Oertel WH, Höglinger GU.

Exp Neurol. 2009 Nov;220(1):133-42. doi: 10.1016/j.expneurol.2009.08.004. Epub 2009 Aug 13.

PMID:
19682988
12.

Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39.

Sakaue F, Saito T, Sato Y, Asada A, Ishiguro K, Hasegawa M, Hisanaga S.

J Biol Chem. 2005 Sep 9;280(36):31522-9. Epub 2005 Jul 1.

13.

Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A.

Liu J, Wang D, Li SQ, Yu Y, Ye RD.

J Neuroinflammation. 2016 Feb 2;13:28. doi: 10.1186/s12974-016-0493-y.

14.

Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau.

Tackenberg C, Brandt R.

J Neurosci. 2009 Nov 18;29(46):14439-50. doi: 10.1523/JNEUROSCI.3590-09.2009.

15.

Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice.

Egashira N, Iwasaki K, Takashima A, Watanabe T, Kawabe H, Matsuda T, Mishima K, Chidori S, Nishimura R, Fujiwara M.

Brain Res. 2005 Oct 12;1059(1):7-12. Epub 2005 Sep 21.

PMID:
16182262
16.

Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice.

Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, Strunk E, Ikezu T.

FASEB J. 2010 Aug;24(8):2904-15. doi: 10.1096/fj.09-150144. Epub 2010 Mar 30.

PMID:
20354135
17.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
18.

Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.

Britschgi M, Takeda-Uchimura Y, Rockenstein E, Johns H, Masliah E, Wyss-Coray T.

J Neuroinflammation. 2012 Sep 18;9:220. doi: 10.1186/1742-2094-9-220.

19.
20.

Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice.

Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, Ishiguro K, Hasegawa M, Yen SH, Chishti MA, Harigaya Y, Abe K, Okamoto K, St George-Hyslop P, Westaway D.

Am J Pathol. 2005 Feb;166(2):521-31.

Supplemental Content

Support Center